Key Points
- Group Walters bought 6,459,973 shares of Zentalis on Dec. 31 at an average price of $1.20, increasing its direct holding to 13,509,973 shares (a 91.63% position increase) in a transaction worth about $7.75 million.
- Zentalis stock jumped 17.4% and opened at $2.84; the company has a market cap of about $205.2M, a 12‑month trading range of $1.01–$3.06, reported quarterly EPS of ($0.37) beating estimates, and is forecast to post roughly -2.42 EPS for the fiscal year.
- Analysts are mixed with a consensus "Hold" rating and a $4.53 target, while institutional investors (including JPMorgan and Bank of America) significantly increased their stakes in the third quarter.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) major shareholder Group Walters bought 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, December 31st. The shares were bought at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the acquisition, the insider directly owned 13,509,973 shares in the company, valued at $16,211,967.60. This trade represents a 91.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Zentalis Pharmaceuticals Stock Up 17.4%
Zentalis Pharmaceuticals stock opened at $2.84 on Friday. The company's 50-day moving average price is $1.43 and its two-hundred day moving average price is $1.48. The stock has a market cap of $205.19 million, a P/E ratio of -1.37 and a beta of 1.75. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $3.06.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.12. Equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Leerink Partners reiterated a "market perform" rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, November 16th. Morgan Stanley dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 12th. Finally, Wedbush reissued a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $4.53.
View Our Latest Report on Zentalis Pharmaceuticals
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in shares of Zentalis Pharmaceuticals by 31.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company's stock worth $1,092,000 after buying an additional 172,628 shares in the last quarter. XTX Topco Ltd boosted its stake in Zentalis Pharmaceuticals by 107.2% in the third quarter. XTX Topco Ltd now owns 548,629 shares of the company's stock valued at $828,000 after buying an additional 283,800 shares in the last quarter. Voleon Capital Management LP bought a new position in Zentalis Pharmaceuticals in the third quarter valued at about $41,000. Qube Research & Technologies Ltd grew its position in Zentalis Pharmaceuticals by 76.4% in the third quarter. Qube Research & Technologies Ltd now owns 56,639 shares of the company's stock valued at $86,000 after acquiring an additional 24,526 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Zentalis Pharmaceuticals by 117.1% during the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company's stock worth $2,339,000 after acquiring an additional 835,466 shares in the last quarter.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
